Could a simple drug tweak metabolism in obesity?
NCT ID NCT05028803
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether sodium phenylbutyrate can lower levels of branched chain amino acids (BCAAs) in the blood of obese and prediabetic men. High BCAAs are linked to insulin resistance and type 2 diabetes. Researchers also looked at how the drug affects blood sugar, insulin sensitivity, and muscle protein building. The trial involved 8 men and was completed at the University of Nottingham.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sodium phenylbutyrate
What this could lead to
If successful, this could point toward a way to improve metabolic health in people with obesity or prediabetes by lowering certain amino acids.
What could go wrong
This is a very small, early-stage study with only 8 participants, so results may not apply to the general population. The drug may not meaningfully affect blood sugar or insulin sensitivity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Nottingham
Derby, Derbyshire, DE22 3NE, United Kingdom